Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVE: Tinzaparin for VTE Prophylaxis in Metastatic Lung Cancer
NCT03090880Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tinzaparin in venous thromboembolism (VTE), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2018; status: terminated.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03090880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090880.